Systemic Treatment for Brain Metastasis and Leptomeningeal Disease in Breast Cancer Patients
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Systemic Treatment for Brain Metastasis and Leptomeningeal Disease in Breast Cancer Patients
Authors
Keywords
-
Journal
Current Oncology Reports
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-11-04
DOI
10.1007/s11912-023-01468-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan
- (2023) Laura Alder et al. npj Breast Cancer
- Trastuzumab Deruxtecan in Patients with Central Nervous System Involvement from HER2-Positive Breast Cancer: The DEBBRAH Trial
- (2022) José Manuel Pérez-García et al. NEURO-ONCOLOGY
- Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
- (2022) Javier Cortés et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic Factors and Survival According to Tumor Subtype in Women With Breast Cancer Brain Metastases
- (2022) Sarah Lopes et al. CURRENT PROBLEMS IN CANCER
- Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial
- (2022) Rupert Bartsch et al. NATURE MEDICINE
- A Phase I/II Study of Intrathecal Trastuzumab in HER-2 Positive Cancer with Leptomeningeal Metastases: Safety, Efficacy, and Cerebrospinal Fluid Pharmacokinetics
- (2022) Priya U Kumthekar et al. NEURO-ONCOLOGY
- Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
- (2022) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
- (2022) Hope S. Rugo et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase II Single-arm Study of Palbociclib in Patients With HER2-positive Breast Cancer With Brain Metastases and Analysis of ctDNA in Patients With Active Brain Metastases
- (2022) Ami N. Shah et al. Clinical Breast Cancer
- Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
- (2022) Sara A Hurvitz et al. LANCET
- Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases
- (2022) Nancy U. Lin et al. JAMA Oncology
- Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study
- (2021) Nancy U. Lin et al. JOURNAL OF CLINICAL ONCOLOGY
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
- (2021) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer.
- (2021) Erica Michelle Stringer-Reasor et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial
- (2021) Sara A. Hurvitz et al. ONCOLOGIST
- Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis
- (2021) G. Curigliano et al. ANNALS OF ONCOLOGY
- ANG1005, a brain penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases
- (2020) Priya Kumthekar et al. CLINICAL CANCER RESEARCH
- Estrogen, Progesterone and HER2 Receptor Discordance Between Primary Tumor and Brain Metastases in Breast Cancer and Its Effect on Treatment and Survival
- (2020) Paul W Sperduto et al. NEURO-ONCOLOGY
- Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis
- (2020) Priscilla K. Brastianos et al. NATURE MEDICINE
- Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial☆
- (2020) F. Montemurro et al. ANNALS OF ONCOLOGY
- A Phase 2 Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer
- (2020) Sara M Tolaney et al. CLINICAL CANCER RESEARCH
- Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
- (2020) Cristina Saura et al. JOURNAL OF CLINICAL ONCOLOGY
- Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial
- (2020) K. Kalinsky et al. ANNALS OF ONCOLOGY
- Treatment strategies for breast cancer brain metastases
- (2020) Caroline Bailleux et al. BRITISH JOURNAL OF CANCER
- The Incidence of Brain Metastases Among Patients with Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
- (2020) Markus Kuksis et al. NEURO-ONCOLOGY
- The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
- (2019) George W. Sledge et al. JAMA Oncology
- Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort
- (2019) Amélie Darlix et al. BRITISH JOURNAL OF CANCER
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
- (2017) George W. Sledge et al. JOURNAL OF CLINICAL ONCOLOGY
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
- (2017) Matthew P. Goetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases
- (2016) Rachel A. Freedman et al. JOURNAL OF CLINICAL ONCOLOGY
- The prognosis analysis of different metastasis pattern in patients with different breast cancer subtypes: a SEER based study
- (2016) Haiyong Wang et al. Oncotarget
- The use of stereotactic radiosurgery for brain metastases from breast cancer: Who benefits most?
- (2015) Eunpi Cho et al. BREAST CANCER RESEARCH AND TREATMENT
- Bevacizumab Preconditioning Followed by Etoposide and Cisplatin Is Highly Effective in Treating Brain Metastases of Breast Cancer Progressing from Whole-Brain Radiotherapy
- (2015) Y.-S. Lu et al. CLINICAL CANCER RESEARCH
- Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial
- (2015) Javier Cortés et al. LANCET ONCOLOGY
- Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets
- (2015) P. K. Brastianos et al. Cancer Discovery
- Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients With Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- (2014) Cristina Saura et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases
- (2013) Nancy U. Lin et al. BREAST CANCER RESEARCH AND TREATMENT
- CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)
- (2013) Bernhard C Pestalozzi et al. LANCET ONCOLOGY
- Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype
- (2012) Nils D. Arvold et al. BREAST CANCER RESEARCH AND TREATMENT
- A European Organisation for Research and Treatment of Cancer Phase III Trial of Adjuvant Whole-Brain Radiotherapy Versus Observation in Patients With One to Three Brain Metastases From Solid Tumors After Surgical Resection or Radiosurgery: Quality-of-Life Results
- (2012) Riccardo Soffietti et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study
- (2012) Thomas Bachelot et al. LANCET ONCOLOGY
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases
- (2011) R Bartsch et al. BRITISH JOURNAL OF CANCER
- Effect of Tumor Subtype on Survival and the Graded Prognostic Assessment for Patients With Breast Cancer and Brain Metastases
- (2011) Paul W. Sperduto et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases
- (2011) Nancy U. Lin et al. JOURNAL OF NEURO-ONCOLOGY
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
- (2011) Javier Cortes et al. LANCET
- Incidence of and survival following brain metastases among women with inflammatory breast cancer
- (2010) S. Dawood et al. ANNALS OF ONCOLOGY
- An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer
- (2009) G. Capri et al. ANNALS OF ONCOLOGY
- Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients
- (2009) Y H Park et al. BRITISH JOURNAL OF CANCER
- Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer
- (2009) N. U. Lin et al. CLINICAL CANCER RESEARCH
- Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients
- (2009) Cyrus Chargari et al. JOURNAL OF NEURO-ONCOLOGY
- Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer
- (2008) Nancy U. Lin et al. CANCER
- Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases
- (2008) Raffaele Addeo et al. CANCER
- Phase II Trial of Lapatinib for Brain Metastases in Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- (2008) Nancy U. Lin et al. JOURNAL OF CLINICAL ONCOLOGY
- A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies
- (2008) Morris D. Groves et al. NEURO-ONCOLOGY
- A New Prognostic Index and Comparison to Three Other Indices for Patients With Brain Metastases: An Analysis of 1,960 Patients in the RTOG Database
- (2007) Paul W. Sperduto et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now